Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

The insulins available without a prescription come in vials and pens that may need ... teamed up with drugmaker Novo Nordisk to sell its own brand, called ReliOn insulin, which sells for as ...

Although no randomized clinical trials using U-500 insulin have been performed, eight case series (involving ... Actrapid U-500, Novo Nordisk in the United Kingdom [voluntarily withdrawn in ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 21 trades. If we consider the ...

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...